Dr. Kudchadkar on BRAF and MEK Inhibitors in Melanoma

Ragini Kudchadkar, MD
Published Online: Friday, October 4, 2013
Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.

Early data demonstrated that the combination of BRAF and MEK inhibitors improve outcomes compared with single agents in patients with melanoma, Kudchadkar says.

If only one pathway is blocked, Kudchadkar says, the cancer cell figures out how to overcome the blockage with time. By combining the agents, the mechanism of resistance from the cancer cell is blocked. This allows patients to stay on therapy longer and decreases skin toxicities that are seen in single agent use.

Kudchadkar believes that it is likely that the combination will become the next standard of care.

Online CME Activities
Free CME from PER
Evolving Management Strategies for Triple-Negative Breast Cancer
Community Practice Connections™: Current and Emerging Strategies in the Management of Early Breast Cancer
Cancer Summaries and Commentaries™: Update from Vienna: Advances in the Treatment of Gastrointestinal Cancers
Advances in Targeted Therapy: The Emerging Role of PARP Inhibitors in the Treatment of Cancers
More Reading